River Renal Companies were founded by Bain Capital Life Sciences in partnership with Narrow River Management in 2020. Narrow River seeks to identify and license promising molecules that have been deprioritized by pharmaceutical companies and to develop them in indications with high medical need for which the current standard of care is inadequate. River Renal Companies are advancing the development of novel therapies targeting orphan diseases in the renal space.
Bain Capital Healthcare
We have built one of the largest and deepest healthcare investing teams in the world. Click here to read more about the breadth and legacy of our efforts.